Overview

The Impact of Renal Impairment on the Pharmacokinetic and Pharmacodynamic of LEO 27847

Status:
Completed
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
The study will investigate the impact of reduced renal function on the pharmacokinetic and pharmacodynamic profile of LEO 27847. Volunteers with different degrees of renal impairment will be administered one dose of the investigational drug and then followed until investigational drug is eliminated from the body.
Phase:
Phase 1
Details
Lead Sponsor:
LEO Pharma